Nurix Therapeutics officer proposes $263K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Nurix Therapeutics, Inc. officer Christine Ring reported a proposed sale of 11,008 common shares, with an aggregate market value of $263,201.28 and an approximate sale date of July 2, 2026. The reported common shares outstanding were 103,405,813. Ring acquired 11,008 shares on July 2, 2026, through exercise of stock options, with cash listed as the payment method. The reported plan adoption or instruction date is November 10, 2025.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Exercise of Stock Options financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What prior NRIX sales did Christine Ring report?
AI-generated analysis. How Rhea-AI works. Not financial advice.